On December 16, 2024, PepGen issued a press release "announc[ing] that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New ...
A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...
UK MHRA grants conditional marketing authorisation to Italfarmaco’s givinostat to treat patients with Duchenne muscular dystrophy: United Kingdom Tuesday, December 24, 2024, 12: ...
A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...